格拉替雷与干扰素β-1a治疗反应评分
该研究比较格拉替雷(GA)与肌注干扰素β-1a(IFN-β-1a)的疗效,利用CombiRx随机试验和MSBase观察队列构建并验证治疗反应评分。评分由年龄、性别、既往年复发次数、病程和EDSS组成,可识别GA相对IFN-β-1a获益更大的人群,结果在MSBase中重复验证。
要点
- CombiRx试验中GA与IFN-β-1a总体ARR比值为0.72。
- 低评分四分位组GA相对IFN-β-1a的ARR比值为0.40(95%CI 0.25-0.63)。
- 评分异质性在CombiRx(p=0.012)和MSBase(p<0.0001)中均显著。
核心结论
- 基于患者特征的治疗反应评分可用于选择GA或IFN-β-1a治疗。
- 该结果在独立真实世界队列MSBase中重复验证。
研究设计与样本
- 研究使用2个独立多发性硬化数据集:CombiRx随机试验(评估GA vs IFN-β-1a)和MSBase观察队列。
- 通过回归年化复发率(ARR)对基线预测因子构建并验证治疗反应评分。
主要发现
- CombiRx试验中GA与IFN-β-1a总体ARR比值为0.72。
- 评分最低四分位组ARR比值为0.40(95%CI 0.25-0.63),中间两个四分位组为0.90(95%CI 0.61-1.34),最高四分位组为1.14(95%CI 0.59-2.18),异质性p=0.012。
- MSBase队列对应ARR比值分别为0.58(95%CI 0.46-0.72)、0.92(95%CI 0.77-1.09)和1.29(95%CI 0.97-1.71),异质性p<0.0001。
关键数值与推荐
- 治疗反应评分由年龄、性别、前一年复发次数、疾病 duration 和EDSS评分的线性组合构成。
- 评分较低(最低四分位)提示GA相对IFN-β-1a的ARR更低。
- 评分较高(最高四分位)提示GA相对IFN-β-1a的ARR无优势。
临床怎么用
- 临床可依据该评分辅助决定复发缓解型多发性硬化患者选用GA还是IFN-β-1a。
- 评分低者可能从GA治疗中获益更多,评分高者可能无明显差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p < 0.0001). CONCLUSIONS: We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
引用
- Bovis F, Kalincik T, Lublin F, et al. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. Neurology. 2020. PMID: 33024022. doi:10.1212/WNL.0000000000010991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。